Mesoblast (MESO) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mesoblast Limited, a global leader in allogeneic cellular medicines, has announced that the FDA has accepted its Biologics License Application for Ryoncil®, aimed at treating children with steroid-refractory acute graft versus host disease (SR-aGVHD). If approved, Ryoncil® would be the first ‘off-the-shelf’ cellular medicine in the US and the first cell therapy for children up to 18 years suffering from this condition. The FDA’s decision is expected by January 7, 2025, following promising clinical trial results showing significant improvement in survival rates.
For further insights into MESO stock, check out TipRanks’ Stock Analysis page.